Page contentsPage contents Key facts Decision Key facts Active substance lunsekimig Therapeutic area Respiratory, thoracic and mediastinal disorders Decision number EMA/PE/0000240621 PIP number EMA/PE/0000240621 Pharmaceutical form(s) Solution for injection Condition(s) / indication(s) Treatment of nasal polyposis Route(s) of administration Subcutaneous use Contact for public enquiries Sanofi Winthrop IndustrieE-mail: catherine.anselmino@sanofi.com Tel.: 0640438252 Decision type P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) Decision date 16/05/2025 Compliance check done No Decision EMA/PE/0000240621 : EMA decision of 16 May 2025 on the granting of a product specific waiver for lunsekimigAdopted Reference Number: EMADOC-1700519818-2114010 English (EN) (227 KB - PDF)First published: 14/07/2026 View Share this page